Market Research Logo

United Kingdom Genetic Testing Market Outlook to 2024

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Genetic Testing Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Genetic Testing Market, United Kingdom
3.1 Genetic Testing Market, United Kingdom, Revenue ($m), 2010-2017
3.2 Genetic Testing Market, United Kingdom, Revenue ($m), 2017-2024
3.3 Genetic Testing Market, United Kingdom, Distribution Share by Revenue ($m), 2017
3.4 Genetic Testing Market, United Kingdom, Company Share by Revenue ($m), 2017
4 Overview of Key Companies in United Kingdom, Genetic Testing Market
4.1 F. Hoffmann-La Roche Ltd
4.1.1 Company Overview
4.2 PerkinElmer Inc
4.2.1 Company Overview
4.3 Abbott Laboratories
4.3.1 Company Overview
4.4 Hologic Inc
4.4.1 Company Overview
4.5 Qiagen NV
4.5.1 Company Overview
4.6 Myriad Genetics Inc
4.6.1 Company Overview
5 Genetic Testing Market Pipeline Products
6 Financial Deals Landscape
6.1 Asset Transactions
6.1.1 Agilent Technologies Acquires Next Generation Sequencing IP Portfolio from Population Genetics Technologies
6.2 Equity Offerings
6.2.1 Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares
6.2.2 Proteome Sciences Raises USD1.3 Million in Second and Final Tranche of Private Placement of Shares
6.2.3 Proteome Sciences Raises USD2.8 Million in First Tranche of Private Placement of Shares
6.3 Partnerships
6.3.1 NuGEN Technologies Enters into Agreement with Cambridge Epigenetix
6.3.2 AstraZeneca Enters into Partnership with DNAnexus
6.3.3 Lucigen Enters into Distribution Agreement with Illumina
6.3.4 SenzaGen Enters into Agreement with AstraZeneca
6.3.5 Sophia Genetics Enters into Agreement with Horizon Discovery Group
6.4 Venture Financing
6.4.1 Biofortuna Raises USD2 Million in Venture Financing
6.4.2 Congenica Raises USD10 Million in Series B Financing
6.4.3 Atlas Genetics Raises USD35 Million in Series D Financing
7 Recent Developments
7.1 Corporate Communications
7.1.1 Oct 03, 2017: Atlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman
7.1.2 Oct 03, 2017: Atlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman
7.1.3 Sep 15, 2017: Oxford BioDynamics appoints Paul Stockdale as Chief Financial Officer and Executive Director on the Board
7.1.4 Sep 01, 2017: Pfizer Receives FDA Approval for Mylotarg (Gemtuzumab Ozogamicin)
7.1.5 Sep 01, 2017: Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS (abaloparatide) Injection
7.1.6 Aug 01, 2017: Proteome Sciences: Directorate changes
7.1.7 Jun 30, 2017: Oxford BioDynamics: Appointment of Paul Stockdale as Chief Financial Officer
7.1.8 Apr 03, 2017: Proteome Sciences Announces Appointment of Richard Dennis as Chief Commercial Officer
7.1.9 Mar 09, 2017: Oxford BioDynamics announces appointment of Martin Reeves as Senior Vice President of Commercial Development
7.1.10 Feb 16, 2017: Almac Diagnostics Appoints Dr Leeona Galligan as Vice President UK Operations
7.1.11 Feb 13, 2017: Oxford BioDynamics appoints Dr Claudio Carini as an Advisor
7.2 Financial Announcements
7.2.1 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017
7.2.2 Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific
7.2.3 Jun 13, 2017: Oxford Biodynamics Interim Results For The Six-Month Period Ended 31 March 2017
7.2.4 Mar 28, 2017: Proteome Sciences Announces Preliminary results for the year ended 31 December 2016 Notice of AGM
7.2.5 Jan 31, 2017: Oxford BioDynamics Announces Final Results for the Year Ended 30 September 2016
7.2.6 Nov 28, 2016: Toshiba Medical Launches New MR System for Efficient and Standardized Cardiac Exams
7.2.7 Nov 22, 2016: OGT announces commercial and financial highlights for FY 2016
7.3 Government and Public Interest
7.3.1 Feb 22, 2017: NICE recommends wider use of tests to detect cancer-causing genetic condition
7.3.2 Nov 15, 2016: One thousand cancer patients have gene testing through efficient, affordable new process
7.4 Legal And Regulatory
7.4.1 Oct 23, 2017: Almac Group Announces Successful MHRA Inspection at Charnwood Facilities
7.4.2 Oct 18, 2017: Proteome Sciences: GCLP Accreditation and Trading Update
7.4.3 Jul 03, 2017: Premaitha Health Litigation Update
7.4.4 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
7.4.5 Jun 12, 2017: Proteome Sciences: New Registered Address
7.5 Other Significant Developments
7.5.1 Jun 07, 2017: Almac Group Reports Pre-tax Profits of £27M
7.5.2 May 25, 2017: Saphetor Signs Multiple Service Agreements with University College London to Analyze Exome and Whole-Genome Sequencing Data
7.5.3 Jan 23, 2017: Oxford BioDynamics enters into pilot project with EpiFit to analyse the effect of fitness regimes using EpiSwitch
7.5.4 Nov 17, 2016: Horizon Discovery Partners with Sophia Genetics on NGS Reference Standards for Oncology Applications
7.6 Product News
7.6.1 Oct 03, 2017: Oxford BioDynamics announces grant of US patent for its proprietary technology platform, EpiSwitch
7.6.2 Aug 21, 2017: Safer Down’s test for pregnant women to be introduced in Wales
7.6.3 May 31, 2017: Nature (Scientific Reports) publication highlights advantages of EpiSwitch technology platform
7.6.4 Apr 25, 2017: OGT’s expanded NGS cancer panels enable sequencing of difficult genes
7.6.5 Jan 25, 2017: New generation Syngene gel doc systems for gel and blot imaging to be showcased on stand 140 at ArabLab 2017
7.6.6 Jan 16, 2017: genedrive Reports Delivery of Genedrive Units and Assays to the US Department of Defense in Programme to Develop a Handheld Biohazard Identifier
7.6.7 Dec 12, 2016: Oxford BioDynamics presents applications of its epigenetic biomarker technology EpiSwitch at the annual meeting of the American Society of Hematology in San Diego
7.7 Strategy And Business Planning
7.7.1 Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK
7.7.2 Nov 10, 2016: Almac Announce £27 million Global Expansion
8 Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer
1.1 List of Tables
Table 1: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2010-2017
Table 2: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2017-2024
Table 3: Genetic Testing Market, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2017
Table 4: Genetic Testing Market, United Kingdom, Company Share by Revenue ($m), USD Constant, 2017
Table 5: Genetic Testing Market Pipeline Products
Table 6: Agilent Technologies Acquires Next Generation Sequencing IP Portfolio from Population Genetics Technologies
Table 7: Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares
Table 8: Proteome Sciences Raises USD1.3 Million in Second and Final Tranche of Private Placement of Shares
Table 9: Proteome Sciences Raises USD2.8 Million in First Tranche of Private Placement of Shares
Table 10: NuGEN Technologies Enters into Agreement with Cambridge Epigenetix
Table 11: AstraZeneca Enters into Partnership with DNAnexus
Table 12: Lucigen Enters into Distribution Agreement with Illumina
Table 13: SenzaGen Enters into Agreement with AstraZeneca
Table 14: Sophia Genetics Enters into Agreement with Horizon Discovery Group
Table 15: Biofortuna Raises USD2 Million in Venture Financing
Table 16: Congenica Raises USD10 Million in Series B Financing
Table 17: Atlas Genetics Raises USD35 Million in Series D Financing
Table 18: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
1.2 List of Figures
Figure 1: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2010-2017
Figure 2: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2017-2024
Figure 3: Genetic Testing Market, United Kingdom, Company Share (%) 2017

United Kingdom Genetic Testing Market Outlook to 2024

Summary

GlobalData’s new report, United Kingdom Genetic Testing Market Outlook to 2024, provides key market data on the United Kingdom Genetic Testing market. The report provides value, in millions of US dollars within market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Genetic Testing market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
  • 2017 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United Kingdom Genetic Testing market.
  • Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories and Luminex Corp.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;